Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.70 |
| ▸ | CA1 | P00915 | 1/20 | 0.70 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.66 |
| ▸ | BIRC2 | Q13490 | 5/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.45 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19522393 | 1.00 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2ABCB1 | |
| SCHEMBL16950292 | 1.00 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2ABCB1 | |
| SCHEMBL967598 | 1.00 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2ABCB1 | |
| SCHEMBL18597131 | 1.00 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2ABCB1 | |
| SCHEMBL18429981 | 1.00 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2ABCB1 | |
| SCHEMBL21356697 | 1.00 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2ABCB1 | |
| SCHEMBL17199802 | 1.00 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2ABCB1 | |
| SCHEMBL21356682 | 1.00 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2ABCB1 | |
| SCHEMBL21356686 | 1.00 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2ABCB1 | |
| SCHEMBL21356695 | 1.00 | CA2 (0.70) | CA2CA1ZDHHC7BIRC2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687854-A2 | LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY | Flagship Labs 114, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024211865-A2 | LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY | OMEGA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230216082-A1 | POLYELECTROLYTE COMPOSITES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-07-06 | — | — | US | disclosed |
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORPORATION | 2023-04-20 | — | — | US | disclosed |
| US-20210386065-A1 | MIXTURE OF MECTINS AND PYRETHROIDS AND USES THEREOF | VALENT BIOSCIENCES LLC | 2021-12-16 | — | — | US | disclosed |
| US-20200323858-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-10-15 | — | — | US | disclosed |
| US-9802939-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-7252886-B2 | Curable composition and process for producing cured fluorinated product | ASAHI GLASS COMPANY, LIMITED (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20060281883-A1 | Curable composition and process for producing cured fluorinated product | ASAHI GLASS COMPANY LIMITED (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1724291-A1 | CURABLE COMPOSITION AND PROCESS FOR PRODUCING CURED FLUOROCHEMICAL | Asahi Glass Company, Limited (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121440-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CA2 4188/4885CA1 4671/4885ZDHHC7 1723/4885 |
| US-20210386065-A1 | MIXTURE OF MECTINS AND PYRETHROIDS AND USES THEREOF | ACHE, DDT, PTMS | CA2 2344/4885CA1 2403/4885ZDHHC7 3946/4885 |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | CA2 2407/4885CA1 3492/4885ZDHHC7 1701/4885 |
| US-11819505-B2 | Heterocyclylamines as PI3K inhibitors | PIK3CA, PIK3CD, PIK3CB | CA2 4188/4885CA1 4671/4885ZDHHC7 1723/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | CA2 2962/4885CA1 2624/4885ZDHHC7 3802/4885 |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | CA2 4200/4885CA1 3794/4885ZDHHC7 220/4885 |
| US-20200323858-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | CA2 4188/4885CA1 4671/4885ZDHHC7 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.